



## PRESS RELEASE

Code: 05/BIAC/11

**For Immediate Release**

**For further information, please contact:**

Erik Walldén, President and CEO

+46 70 225 2270

**Scientific/Trade Press Enquiries:**

Sue Cresswell, Market Communication Director

+41 (0) 79710 8311

### **New Order for Biacore® A100 Received from Major Pharmaceutical Company**

#### **Commercial Roll-Out of State of the Art System Continues at Several Major Protein Science Conferences**

**Uppsala, Sweden, September 12, 2005.** Biacore International AB (SSE: BCOR) is pleased to report further commercial progress with Biacore® A100, its most advanced array system for protein interaction analysis.

Biacore has today received its second order for Biacore® A100 from one of the world's major European based pharmaceutical companies which intends to utilize the system to enhance its bio-therapeutic screening capabilities.

In addition, Biacore® A100 was highlighted at the Developments in Protein Interaction Analysis Conference (DiPIA) on August 28-31, in Philadelphia, USA. The DiPIA conference, sponsored by Biacore, offered more than 300 participants the opportunity to exchange and discuss information on new applications and specific methodologies in protein interaction analysis using Biacore® A100. At the conference, a number of papers were presented, both by academic and industrial researchers, which highlighted the unique data that can be generated using Biacore® A100 for a range of small molecule and antibody screening applications\*. Organizations which made presentations on working with Biacore® A100 included: the University of Utah, Hoffman La-Roche, Glaxo SmithKline and the Japanese

Biological Informatics Consortium that works closely with Biacore's first customer, The National Institute of Advanced Industrial Science and Technology (AIST), Japan.

Biacore also showcased Biacore®A100 at HUPO 4<sup>th</sup> Annual World Conference on August 28<sup>th</sup> to September 1<sup>st</sup> in Munich, Germany, where the focus of the meeting was on protein interactions. Biacore®A100 will also be highlighted at the SBS 11<sup>th</sup> Annual Conference and Exhibition in Geneva, Switzerland on September 11- 15.

These important industry events also marked the product's planned roll-out to the Company's mainstream sales force. Previously the system had been marketed by a dedicated team comprising both business development and research personnel.

Erik Walldén, Biacore's President and CEO said: "I am pleased to announce Biacore's second commercial order for Biacore®A100 to a major pharmaceutical company. The introduction of this powerful new product using a small specialist team is now successfully concluded, and the commercialization of Biacore®A100 is now in a new phase being marketed through our regular marketing and sales organization. The exciting screening data which was presented at the DiPIA, HUPO and SBS conferences is the result of a number of very successful academic and industrial collaborations and will greatly assist Biacore's general sales force in creating further commercial interest in this exciting product."

\* A complete program covering all of the presentations at the Developments in Protein Interaction Analysis Conference (DiPIA) are available at [www.biacore.com](http://www.biacore.com).

- Ends -

#### **About Biacore®A100 array based platform**

Biacore®A100 has been designed and developed for use in a broad range of applications in proteomics, early kinetic screening of antibody therapeutics and in many areas within drug discovery including hit validation, compound library screening particularly from virtual screens and fragment libraries, lead optimization and also in pre-clinical studies.

Biacore®A100 rapidly monitors protein interactions (thousands of interactions per day) to generate high quality kinetic, affinity and selectivity of binding information.

Biacore®A100 enables multiplex kinetic screening of protein panels providing unique selectivity information. The parallel real-time analysis of protein interactions combines increased throughput with the sensitivity needed to handle small molecule analysis. The array technology brings a new dimension to the study of protein interactions by using parallel analysis to generate crucial information on the behavior and interactions of a wide range of proteins grouped into panels or other configurations. The system also includes new software tools that have been optimized for array applications and are designed to handle large data volumes.

## **About Biacore**

*Biacore is a global supplier of analytical systems that improve the productivity of research and development in the life science and pharmaceutical markets. The company's instruments generate unique data on protein interactions, an area of increasing focus in these markets. The data give insights into protein functionality, the role of proteins in normal and diseased states, and the influence of potential drug candidates.*

*Use of Biacore products is well-documented in key areas such as antibody characterization, proteomics, lead optimization and bio-therapeutic development and production. Customers include world renowned life science research centers, all of the leading global pharmaceutical companies and a large number of companies in the emerging biotechnology sector.*

*Biacore is successfully expanding into the food analysis market, providing key manufacturers with ready-to-use solutions for the determination of food quality and safety.*

*The company offers a range of products to meet specific customer needs. All instruments utilize Surface Plasmon Resonance (SPR) technology as the basis for detection and monitoring of protein interactions.*

*Biacore has its own direct sales capability in the world's key markets, United States, Europe, Japan, Australia and a distribution network in Asia-Pacific. The company was created in 1984, is based in Uppsala, Sweden, and is listed on the Stockholm Stock Exchange [www.stockholmsborsen.se](http://www.stockholmsborsen.se) (SSE: BCOR).*